Comparative performance of the InBios SCoV-2 DetectTM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations
Open Access
- 28 July 2025
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 9, 349
Abstract
Background The InBios SCoV-2 Detect™ IgG ELISA (InBios) and the in-house KWTRP ELISA (KWTRP) have both been used in the estimation of SARS-CoV-2 seroprevalence in Kenya. Whereas the latter has been validated extensively using local samples, the former has not. Such validation is important for informing the comparability of data across the sites and populations where seroprevalence has been reported. Methods We compared the assays directly using pre-pandemic serum/plasma collected in 2018 from 454 blood donors and 173 malaria cross-sectional survey participants, designated gold standard negatives. As gold standard SARS-CoV-2 positive samples: we assayed serum/plasma from 159 SARS-CoV-2 PCR-positive patients and 166 vaccination-confirmed participants. Results The overall agreement on correctly classified samples was >0.87 for both assays. The overall specificity was 0.89 (95% CI, 0.87–0.91) for InBios and 0.99 (95% CI, 0.97–0.99) for KWTRP among the gold standard negative samples while the overall sensitivity was 0.97 (95% CI, 0.94–0.98) and 0.93 (95% CI, 0.90– 0.95) for InBios and KWTRP ELISAs respectively, among the gold standard positive samples. In all, the positive predictive value for InBios was 0.83 (95% CI, 0.79-0.87) and 0.98 (95% CI, 0.96-0.99) for KWTRP while the negative predictive value was 0.98 (95% CI, 0.97- 0.99) and 0.97 (95% CI, 0.95-0.98) for InBios and KWTRP respectively. Conclusions Overall, both assays showed sufficient sensitivity and specificity to estimate SARS-CoV-2 antibodies in different populations in Kenya.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-039626)
- Wellcome Trust (214320)
- Wellcome Trust (203077)
- Wellcome Trust (220991)
This publication has 28 references indexed in Scilit:
- Learning from serosurveillance for SARS-CoV-2 to inform pandemic preparedness and responseThe Lancet, 2023
- SARS-CoV-2 Testing Strategies in the Diagnosis and Management of COVID-19 Patients in Low-Income Countries: A Scoping ReviewMolecular Diagnosis & Therapy, 2023
- Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitroInternational Journal of Infectious Diseases, 2022
- Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populationsJournal of Clinical Virology, 2022
- Performance assessment of seven SARS‐CoV‐2 IgG enzyme‐linked immunosorbent assaysJournal of Medical Virology, 2021
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in KenyaNature Communications, 2021
- Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in KenyaClinical Infectious Diseases, 2021
- High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan AfricaInternational Journal of Infectious Diseases, 2021
- Method agreement analysis: A review of correct methodologyTheriogenology, 2010